Postavení inhibitorů tyrosinkináz v léčbě chronické myeloidní leukemie
| Title in English | The role of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Onkologická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://onkologickarevue.cz/cs/postaveni-inhibitoru-tyrosinkinaz-v-lecbe-chronicke-myeloidni-leukemie |
| Keywords | chronic myeloid leukemia; tyrosine kinase inhibitors; treatment-free remission; interferon alpha |
| Description | Before the introduction of tyrosine kinase inhibitors, the chronic myeloid leukemia patients therapy relied on non-specific agents such as busulfan, hydroxyurea and interferon alpha, with overall survival not exceeding 30%. The discovery of BCR: ABL1 fusion gene, which encodes a constitutively activated tyrosine kinase BCR::ABL1 started a new era of chronic myeloid leukemia therapy. This kinase serves as a target for tyrosine kinase inhibitors such as imatinib, nilotinib, dasatinib, bosutinib, ponatinib and the newest allosteric inhibitor asciminib. With their introduction, the life expectancy of patients with newly diagnosed chronic myeloid leukemia in the chronic phase is almost the same as that of healthy peers. Even though some specific situations still require the use of interferon alpha or allogeneic stem cells transplantation or allow discontinuation of the drug with the achievement of treatment-free remission, tyrosine kinase inhibitors are completely irreplaceable and form the basis of chronic myeloid leukemia therapy. Their fixed position in the first and the following treatment lines in the Czech Republic is comprehensively summarized in the presented work. |